146 related articles for article (PubMed ID: 15371556)
1. Discovery of BRL 50481 [3-(N,N-dimethylsulfonamido)-4-methyl-nitrobenzene], a selective inhibitor of phosphodiesterase 7: in vitro studies in human monocytes, lung macrophages, and CD8+ T-lymphocytes.
Smith SJ; Cieslinski LB; Newton R; Donnelly LE; Fenwick PS; Nicholson AG; Barnes PJ; Barnette MS; Giembycz MA
Mol Pharmacol; 2004 Dec; 66(6):1679-89. PubMed ID: 15371556
[TBL] [Abstract][Full Text] [Related]
2. In vitro differentiation of human monocytes to macrophages: change of PDE profile and its relationship to suppression of tumour necrosis factor-alpha release by PDE inhibitors.
Gantner F; Kupferschmidt R; Schudt C; Wendel A; Hatzelmann A
Br J Pharmacol; 1997 May; 121(2):221-31. PubMed ID: 9154331
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-10 does not mediate the inhibitory effect of PDE-4 inhibitors and other cAMP-elevating drugs on lipopolysaccharide-induced tumors necrosis factor-alpha generation from human peripheral blood monocytes.
Seldon PM; Barnes PJ; Giembycz MA
Cell Biochem Biophys; 1998; 29(1-2):179-201. PubMed ID: 9631245
[TBL] [Abstract][Full Text] [Related]
4. Suppression of lipopolysaccharide-induced tumor necrosis factor-alpha generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase.
Seldon PM; Barnes PJ; Meja K; Giembycz MA
Mol Pharmacol; 1995 Oct; 48(4):747-57. PubMed ID: 7476903
[TBL] [Abstract][Full Text] [Related]
5. Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B.
Manning CD; Burman M; Christensen SB; Cieslinski LB; Essayan DM; Grous M; Torphy TJ; Barnette MS
Br J Pharmacol; 1999 Dec; 128(7):1393-8. PubMed ID: 10602317
[TBL] [Abstract][Full Text] [Related]
6. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro.
Hatzelmann A; Schudt C
J Pharmacol Exp Ther; 2001 Apr; 297(1):267-79. PubMed ID: 11259554
[TBL] [Abstract][Full Text] [Related]
7. Regulation of distinct cyclic AMP-specific phosphodiesterase (phosphodiesterase type 4) isozymes in human monocytic cells.
Verghese MW; McConnell RT; Lenhard JM; Hamacher L; Jin SL
Mol Pharmacol; 1995 Jun; 47(6):1164-71. PubMed ID: 7603456
[TBL] [Abstract][Full Text] [Related]
8. In vitro pharmacology of the novel phosphodiesterase type 4 inhibitor, CP-80633.
Cohan VL; Showell HJ; Fisher DA; Pazoles CJ; Watson JW; Turner CR; Cheng JB
J Pharmacol Exp Ther; 1996 Sep; 278(3):1356-61. PubMed ID: 8819523
[TBL] [Abstract][Full Text] [Related]
9. Identification and quantification of phosphodiesterase 4 subtypes in CD4 and CD8 lymphocytes from healthy and asthmatic subjects.
Landells LJ; Szilagy CM; Jones NA; Banner KH; Allen JM; Doherty A; O'Connor BJ; Spina D; Page CP
Br J Pharmacol; 2001 Jul; 133(5):722-9. PubMed ID: 11429397
[TBL] [Abstract][Full Text] [Related]
10. A biochemical and functional assessment of monocyte phosphodiesterase activity in healthy and asthmatic subjects.
Landells LJ; Spina D; Souness JE; O'Connor BJ; Page CP
Pulm Pharmacol Ther; 2000; 13(5):231-9. PubMed ID: 11003567
[TBL] [Abstract][Full Text] [Related]
11. Anti-inflammatory and utero-relaxant effects in human myometrium of new generation phosphodiesterase 4 inhibitors.
Oger S; Méhats C; Barnette MS; Ferré F; Cabrol D; Leroy MJ
Biol Reprod; 2004 Feb; 70(2):458-64. PubMed ID: 14561639
[TBL] [Abstract][Full Text] [Related]
12. SB 207499 (Ariflo), a second generation phosphodiesterase 4 inhibitor, reduces tumor necrosis factor alpha and interleukin-4 production in vivo.
Griswold DE; Webb EF; Badger AM; Gorycki PD; Levandoski PA; Barnette MA; Grous M; Christensen S; Torphy TJ
J Pharmacol Exp Ther; 1998 Nov; 287(2):705-11. PubMed ID: 9808700
[TBL] [Abstract][Full Text] [Related]
13. Beneficial effects of the phosphodiesterase inhibitors BRL 61063, pentoxifylline, and rolipram in a murine model of endotoxin shock.
Badger AM; Olivera DL; Esser KM
Circ Shock; 1994 Dec; 44(4):188-95. PubMed ID: 7628060
[TBL] [Abstract][Full Text] [Related]
14. Phosphodiesterase (PDE) 7 in inflammatory cells from patients with asthma and COPD.
Jones NA; Leport M; Holand T; Vos T; Morgan M; Fink M; Pruniaux MP; Berthelier C; O'Connor BJ; Bertrand C; Page CP
Pulm Pharmacol Ther; 2007; 20(1):60-8. PubMed ID: 16427796
[TBL] [Abstract][Full Text] [Related]
15. The effect of oxidative stress on macrophages and lung epithelial cells: the role of phosphodiesterases 1 and 4.
Brown DM; Hutchison L; Donaldson K; MacKenzie SJ; Dick CA; Stone V
Toxicol Lett; 2007 Jan; 168(1):1-6. PubMed ID: 17129690
[TBL] [Abstract][Full Text] [Related]
16. Phosphodiesterase inhibitors in airways disease.
Fan Chung K
Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289
[TBL] [Abstract][Full Text] [Related]
17. Effects of ciclamilast, a new PDE 4 PDE4 inhibitor, on airway hyperresponsiveness, PDE4D expression and airway inflammation in a murine model of asthma.
Deng YM; Xie QM; Tang HF; Sun JG; Deng JF; Chen JQ; Yang SY
Eur J Pharmacol; 2006 Oct; 547(1-3):125-35. PubMed ID: 16956605
[TBL] [Abstract][Full Text] [Related]
18. CDP840: a novel inhibitor of PDE-4.
Perry MJ; O'Connell J; Walker C; Crabbe T; Baldock D; Russell A; Lumb S; Huang Z; Howat D; Allen R; Merriman M; Walls J; Daniel T; Hughes B; Laliberte F; Higgs GA; Owens RJ
Cell Biochem Biophys; 1998; 29(1-2):113-32. PubMed ID: 9631241
[TBL] [Abstract][Full Text] [Related]
19. The effects of a novel phosphodiesterase 7A and -4 dual inhibitor, YM-393059, on T-cell-related cytokine production in vitro and in vivo.
Yamamoto S; Sugahara S; Naito R; Ichikawa A; Ikeda K; Yamada T; Shimizu Y
Eur J Pharmacol; 2006 Jul; 541(1-2):106-14. PubMed ID: 16780833
[TBL] [Abstract][Full Text] [Related]
20. Differential inhibitor effects on cyclic adenosine monophosphate-phosphodiesterase isoforms in atopic and normal leukocytes.
Chan SC; Hanifin JM
J Lab Clin Med; 1993 Jan; 121(1):44-51. PubMed ID: 8381148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
